Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 403-412 , March 2010

Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Sclerodermatous Chronic Graft-versus-Host Disease: Clinical Report

  • Hong Zhou

      Affiliations

    • Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    • Both authors contributed equally to this work.
    • ,
  • Mei Guo

      Affiliations

    • Department of Hematology and Transplantation, Affiliated Hospital of Academy of Military Medicine Science, Beijing, People's Republic of China
    • Both authors contributed equally to this work.
    • ,
  • Chunjing Bian

      Affiliations

    • Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    • ,
  • Zhao Sun

      Affiliations

    • Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    • ,
  • Zhuo Yang

      Affiliations

    • Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    • ,
  • Yang Zeng

      Affiliations

    • Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    • ,
  • HuiSheng Ai

      Affiliations

    • Department of Hematology and Transplantation, Affiliated Hospital of Academy of Military Medicine Science, Beijing, People's Republic of China
    • Corresponding Author InformationHuisheng Ai, MD, Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medicine Sciences, Beijing, PR China.
    • ,
  • Robert Chunhua Zhao

      Affiliations

    • Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    • Corresponding Author InformationCorrespondence and reprint requests: Robert Chunhua Zhao, MD, PhD, Center of Excellence in Tissue Engineering, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, PR China.
    • Both authors contributed equally to this work.

Received 28 August 2009 ,Accepted 8 November 2009.

References 

  1. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276
  2. Kim J, Choi WS, Kim HJ, et al. Prevention of chronic graft-versus-host disease by stimulation with glucocorticoid-induced TNF receptor. Exp Mol Med. 2006;38:94–99
  3. Nagler A, Pines M, Abadi U, et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology. 2000;31:641–648
  4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11:945–956
  5. Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23:78–84
  6. Peñas PF, Jones-Caballero M, Aragüés M, et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002;138:924–934
  7. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061–1067
  8. Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood. 1999;94:825–831
  9. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol. 2001;40:205–211
  10. von Bonin M, Oelschlägel U, Radke J, et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation. 2008;86:875–879
  11. Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood. 1999;93:66–70
  12. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30:287–295
  13. Skert C, Patriarca F, Sperotto A, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica. 2006;91:258–261
  14. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–1822
  15. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–48
  16. Deng W, Han Q, Liao L, et al. Effects of allogeneic bone marrow–derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol. 2005;24:458–463
  17. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441
  18. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11:389–398
  19. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–1397
  20. von Bonin M, Stölzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245–251
  21. Guo H, Fang B, Liao L, et al. Hemangioblastic characteristics of fetal bone marrow–derived Flk1(+)CD31(-) CD34(-) cells. Exp Hematol. 2003;31:650–658
  22. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte–derived dendritic cells. Stem Cells Dev. 2004;13:263–271
  23. Clements P, Lachenbruch P, Siebold J, et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–1285
  24. Masubuchi Y, Sugiyama S, Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact. 2009;179:273–279
  25. Guo H, Qiao Z, Zhu L, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients following nonmyeloablative allogeneic stem cell transplantation. Am J Hematol. 2004;75:78–83
  26. Shao DD, Suresh R, Vakil V, et al. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol. 2008;83:1323–1333
  27. Darvay A, Salooja N, Russell-Jones R. The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol. 2004;18:279–284
  28. Deng W, Han Q, Liao L, et al. Allogeneic bone marrow–derived flk-1 + Sca-1- mesnchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol. 2004;32:861–867
  29. Fang B, Shi M, Liao L, et al. Systemic infusion of Flk1+ mesenchymal stem cells ameliorate carbon tetrachloride–induced liver fibrosis in mice. Transplantation. 2004;78:83–88
  30. Yan X, Liu Y, Han Q, et al. Injured microenvironment directly guides the differentiation of engrafted Flk1+ mesenchymal stem cell in lung. Exp Hematol. 2007;35:1466–1475
  31. Liu L, Sun Z, Chen B, et al. Ex vivo expansion and in vivo infusion of bone marrow–derived Flk-1 + CD31-CD34- mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev. 2006;15:349–357
  32. Guo M, Sun Z, Sun QY, et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant. 2009;15:930–937
  33. Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distribution of bone marrow–derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169:12–20
  34. Zhao Z, Liao L, Cao Y, et al. Establishment and properties of fetal dermis-derived mesenchymal stem cell lines: plasticity in vitro and hematopoietic protection in vivo. Bone Marrow Transplant. 2005;36:355–365
  35. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22:593–599
  36. Miflin G, Russell NH, Franklin I, et al. An analysis of the effect of chronic graft-versus-host disease on relapse and survival following allogenic peripheral blood stem cell transplantation. Cytotherapy. 2000;2:423–428

 Financial disclosure: See Acknowledgments on page 411.

PII: S1083-8791(09)00523-0

doi: 10.1016/j.bbmt.2009.11.006

Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 403-412 , March 2010

Article Tools

* Image Usage & Resolution